The pro-oncogenic role of CdGAP in breast7,8 and prostate cancer challenges the existing paradigm and adds to the list of the emerging RhoGAPs acting as positive modulators of cancers6. This evidence concerns the gene ARHGAP31 and prostate carcinoma.